Logo image of IMMX

IMMIX BIOPHARMA INC (IMMX) Stock Fundamental Analysis

NASDAQ:IMMX - US45258H1068 - Common Stock

2.29 USD
+0.33 (+16.84%)
Last: 8/28/2025, 8:18:29 PM
2.3 USD
+0.01 (+0.44%)
After Hours: 8/28/2025, 8:18:29 PM
Fundamental Rating

2

Overall IMMX gets a fundamental rating of 2 out of 10. We evaluated IMMX against 547 industry peers in the Biotechnology industry. IMMX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMMX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMMX had negative earnings in the past year.
IMMX had a negative operating cash flow in the past year.
IMMX had negative earnings in each of the past 5 years.
IMMX had a negative operating cash flow in each of the past 5 years.
IMMX Yearly Net Income VS EBIT VS OCF VS FCFIMMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -147.91%, IMMX is not doing good in the industry: 84.83% of the companies in the same industry are doing better.
The Return On Equity of IMMX (-497.03%) is worse than 76.78% of its industry peers.
Industry RankSector Rank
ROA -147.91%
ROE -497.03%
ROIC N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMMX Yearly ROA, ROE, ROICIMMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMMX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMX Yearly Profit, Operating, Gross MarginsIMMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

IMMX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMMX has more shares outstanding
IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMMX Yearly Shares OutstandingIMMX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IMMX Yearly Total Debt VS Total AssetsIMMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

IMMX has an Altman-Z score of -9.47. This is a bad value and indicates that IMMX is not financially healthy and even has some risk of bankruptcy.
IMMX's Altman-Z score of -9.47 is on the low side compared to the rest of the industry. IMMX is outperformed by 71.48% of its industry peers.
IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.47
ROIC/WACCN/A
WACCN/A
IMMX Yearly LT Debt VS Equity VS FCFIMMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.23 indicates that IMMX should not have too much problems paying its short term obligations.
IMMX has a Current ratio of 1.23. This is amonst the worse of the industry: IMMX underperforms 84.10% of its industry peers.
IMMX has a Quick Ratio of 1.23. This is a normal value and indicates that IMMX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.23, IMMX is doing worse than 83.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
IMMX Yearly Current Assets VS Current LiabilitesIMMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.27% over the past year.
EPS 1Y (TTM)7.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 48.14% on average over the next years. This is a very strong growth
Based on estimates for the next years, IMMX will show a very strong growth in Revenue. The Revenue will grow by 155.56% on average per year.
EPS Next Y15.99%
EPS Next 2Y0.2%
EPS Next 3Y46.2%
EPS Next 5Y48.14%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y223.96%
Revenue Next 5Y155.56%

3.3 Evolution

IMMX Yearly Revenue VS EstimatesIMMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2027 2028 2029 2030 2031 50M 100M 150M
IMMX Yearly EPS VS EstimatesIMMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IMMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMMX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMX Price Earnings VS Forward Price EarningsIMMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMX Per share dataIMMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

IMMX's earnings are expected to grow with 46.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.2%
EPS Next 3Y46.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMMX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMIX BIOPHARMA INC

NASDAQ:IMMX (8/28/2025, 8:18:29 PM)

After market: 2.3 +0.01 (+0.44%)

2.29

+0.33 (+16.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)11-10 2025-11-10
Inst Owners12.32%
Inst Owner Change-22.49%
Ins Owners28.71%
Ins Owner Change0%
Market Cap66.02M
Analysts82.86
Price Target7.14 (211.79%)
Short Float %1.17%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.63%
Min EPS beat(2)-34.8%
Max EPS beat(2)36.06%
EPS beat(4)2
Avg EPS beat(4)-2.14%
Min EPS beat(4)-47.06%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.27%
EPS NY rev (1m)-4.2%
EPS NY rev (3m)23.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.19
P/tB 14.19
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.91%
ROE -497.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 472.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -9.47
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.67%
EPS Next Y15.99%
EPS Next 2Y0.2%
EPS Next 3Y46.2%
EPS Next 5Y48.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y223.96%
Revenue Next 5Y155.56%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.91%
OCF growth 3YN/A
OCF growth 5YN/A